Ameliorative effect of diclofenac in rotenone corneal kindling model of drug-resistant epilepsy: Edge of dual COX and KMO inhibition
Brain Research · 2025
DOI: 10.1016/j.brainres.2024.149246 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain Research, 2025. Verfasst von Samriti und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences & Drug Research, Punjabi University, Patiala, 147002 India. Electronic address: sharmasamriti4715@gmail.com. Hauptthemen laut MEDLINE: Diclofenac, Kindling, Neurologic, Rotenone, Cyclooxygenase Inhibitors. Die Arbeit nennt 55 Literaturangaben.
Abstract (Originalsprache)
Epilepsy affects millions of people worldwide, about one-third patients with epilepsy exhibits resistance to available antiseizures medications, known as drug-resistant epilepsy (DRE). Mitochondrial dysfunction has been implicated as a hallmark in drug-resistant epilepsy via activation of microglial kynurenine 3-monooxygenase (KMO) and cyclooxygenase (COX) enzymes, leading to neuroinflammation and oxidative stress. Diclofenac, an equipotent non selective cyclooxygenase inhibitor, has inhibitory action on KMO enzyme and has also shown anti-inflammatory and antioxidant properties in animal models of epilepsy. These properties make it a suitable candidate for amelioration of DRE. However, its potential in drug-resistant epilepsy remained unexplored till date. In this study, dose dependent effect of diclofenac (5 mg/kg, 10 mg/kg, 20 mg/kg) has been explored in rotenone corneal kindling model of mitochondrial DRE. The results of our study revealed the induction of drug resistance to antiseizure medications and induced kynurenine 3-monooxygenase activity in rotenone corneal kindled epileptic mice in comparison to naive mice. Treatment of rotenone corneal kindled epileptic mice with diclofenac resulted in a significant decrease in drug resistance to antiseizure medications as evident by a reduction in seizure score in the treatment groups as compared to control group, in post-treatment resistance validation. The kynurenine 3-monooxygenase inhibitory activity (as evidenced by decreased levels of neurotoxic quinolinic acid) and the antioxidant effect (as evident by significantly reduced oxidative stress) in the diclofenac treated groups, emerged as a major contributor for its ameliorative action. Findings of this study suggests, diclofenac can be used as an adjunct therapy in amelioration of drug-resistant epilepsy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences & Drug Research, Punjabi University, Patiala, 147002 India. Electronic address: sharmasamriti4715@gmail.com.
- Department of Pharmaceutical Sciences & Drug Research, Punjabi University, Patiala, 147002 India. Electronic address: Arvindercology@gmail.com.
- Department of Pharmaceutical Sciences & Drug Research, Punjabi University, Patiala, 147002 India. Electronic address: arsh96396@gmail.com.
- Department of Pharmaceutical Sciences & Drug Research, Punjabi University, Patiala, 147002 India. Electronic address: goelrkpup@gmail.com.
Zitieren
APA
Samriti, Kaur, A., Kaur, A., & Goel, R. K. (2025). Ameliorative effect of diclofenac in rotenone corneal kindling model of drug-resistant epilepsy: Edge of dual COX and KMO inhibition. Brain Research. https://doi.org/10.1016/j.brainres.2024.149246
Vancouver
Samriti, Kaur A, Kaur A, Goel RK. Ameliorative effect of diclofenac in rotenone corneal kindling model of drug-resistant epilepsy: Edge of dual COX and KMO inhibition. Brain Research. 2025. doi:10.1016/j.brainres.2024.149246
BibTeX
@article{Samriti2025,
author = {Samriti and Kaur, Arvinder and Kaur, Arshbir and Goel, R K},
title = {Ameliorative effect of diclofenac in rotenone corneal kindling model of drug-resistant epilepsy: Edge of dual COX and KMO inhibition},
journal = {Brain Research},
year = {2025},
doi = {10.1016/j.brainres.2024.149246}
}
EUVIMED